Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated: May 06, 2026

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 273    

Filtered results: 273

Review of Hyperkalemia Profile for Mineralocorticoid Receptor Antagonist in Patients with Chronic Kidney Disease and Type 2 Diabetes

Kendrick J., Dixon A., CM. 2026

Kendrick J, 16 07 2026

Characterizing Children with Chronic Kidney Disease and Severe Proteinuria in the United States: A Retrospective Analysis Using Electronic Health Records (STORK-CKD)

Warady B., et al, PN. 2026

Warady B, 14 07 2026

Impact of Air Pollution Exposure on Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Analysis

Al-Kindi S., et al, AJPC. 2026

Al-Kindi S, 19 06 2026

Systolic Blood Pressure and Albuminuria Reduction Mediate Cardiovascular Benefits of Finerenone in T2 Diabetes and CKD

Agarwal R., et al, NDT. 2026

Agarwal R, 16 06 2026

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial

McGill J., et al, DOM. 2026

McHill J, 15 06 2026

Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical Trials

Lo K., et al, JAMA. 2026

Lo KB, 09 06 2026

Finerenone in People with Chronic Kidney Disease without Diabetes

Heerspink H., et al, NEJM. 2026

Heerspink H, 09 06 2026

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial

Beernink J., et al, DC. 2026

Beernink J, 09 06 2026

Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis

Foa A, et al, JAMA. 2026

Foa A, 09 06 2026

Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease: An Individual Participant Data Pooled Analysis (INFINITY)

Neuen B., et al, TL. 2026

Neuen B, 09 06 2026